In our study, we attempted to enhance the survival and therapy response prediction for AML patients through a combined approach that incorporates information on drug responsiveness and the MDR1 mRNA/P-gp expression of leukemic cells at diagnosis into the standard protocol for risk and prognosis stratification. This evidence concerns the gene ABCB1 and acute myeloid leukemia.